flomoxef and ertapenem
flomoxef has been researched along with ertapenem in 3 studies
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, YS; Chiu, CJ; Chu, C; Lee, CH; Liu, JW; Su, LH | 1 |
Chen, CH; Chen, JB; Chiu, CH; Chuang, FR; Lee, CT; Liu, HT; Wu, CH; Yang, CC | 1 |
Cheng, A; Chuang, YC; Sheng, WH; Wang, JT; Yang, JJ | 1 |
Other Studies
3 other study(ies) available for flomoxef and ertapenem
Article | Year |
---|---|
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cephalosporins; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Electroporation; Ertapenem; Female; Genotype; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Cephalosporins; Cross Infection; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Treatment Outcome | 2014 |
Impact of broad-spectrum antimicrobial treatment on the ecology of intestinal flora.
Topics: Acinetobacter baumannii; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Feces; Female; Fluoroquinolones; Gastrointestinal Microbiome; Humans; Male; Microbial Viability; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Taiwan | 2018 |